Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 12/20 | 0.39 |
| ▸ | CA1 | P00915 | 12/20 | 0.39 |
| ▸ | CA2 | P00918 | 12/20 | 0.39 |
| ▸ | CA9 | Q16790 | 12/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.37 |
| ▸ | GHSR | Q92847 | 2/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5200984 | 0.89 | GHSR (0.37) | TGFBR1GHSRMAPK14 | |
| SCHEMBL5199223 | 0.89 | TGFBR1 (0.36) | TGFBR1GHSRMAPK14 | |
| SCHEMBL5198372 | 0.84 | PTGS2 (0.45) | TGFBR1PTGS1PTGS2 | |
| SCHEMBL5198270 | 0.83 | TGFBR1 (0.42) | TGFBR1GHSRPTGS1PTGS2 | |
| SCHEMBL5199511 | 0.82 | TGFBR1 (0.38) | CA12CA1CA2CA9TGFBR1 | |
| SCHEMBL5199208 | 0.82 | TGFBR1 (0.39) | TGFBR1GHSRPTGS1PTGS2 | |
| SCHEMBL5200774 | 0.82 | TGFBR1 (0.39) | CA1CA2CA9TGFBR1GHSR | |
| SCHEMBL5200017 | 0.81 | TGFBR1 (0.39) | TGFBR1MAPK14PTGS2 | |
| SCHEMBL5200347 | 0.80 | TGFBR1 (0.40) | CA12CA1CA2CA9TGFBR1 | |
| SCHEMBL5198993 | 0.80 | TGFBR1 (0.37) | TGFBR1GHSRPTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275968-A1 | Substituted Biphenyl Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-11-29 | — | — | US | claimed |
| EP-1798229-A1 | SUBSTITUTED BIPHENYL DERIVATIVE | Sankyo Company, Limited (JP) | 2007-06-20 | — | — | EP | claimed |
| US-20070275968-A1 | Substituted Biphenyl Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1798229-A1 | SUBSTITUTED BIPHENYL DERIVATIVE | Sankyo Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275968-A1 | Substituted Biphenyl Derivative | COL2A1, COL1A1, FGFR3 | CA12 1900/4885CA1 1466/4885CA2 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.